Stacey E. Rudd
YOU?
Author Swipe
View article: Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab
Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab Open
An antibody for Human Epidermal Growth Factor Receptor 2 (HER2) radiolabelled with copper-67 has high therapeutic efficacy in a mouse model of HER2 positive tumours.
View article: P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT
P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT Open
View article: CCDC 2252368: Experimental Crystal Structure Determination
CCDC 2252368: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2252366: Experimental Crystal Structure Determination
CCDC 2252366: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2252367: Experimental Crystal Structure Determination
CCDC 2252367: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: CCDC 2252369: Experimental Crystal Structure Determination
CCDC 2252369: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo Open
Fully automated production of [89Zr]Zr-DFOSq-Durvalumab for clinical use was achieved with minimal exposure to the operator. The cassette-based approach allows for consecutive productions on the same day and offers an alternativ…
View article: ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with<sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with<sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol Open
Background ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89 Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials. Methods The phase 0 study recru…
View article: Imaging immunity in patients with cancer using positron emission tomography
Imaging immunity in patients with cancer using positron emission tomography Open
View article: Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models
Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models Open
View article: Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor
Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor Open
Enzymatic bioconjugation to introduce positron-emitting radionuclides (89Zr, 64Cu) into an anti-EGFR antibody fragment allows same day imaging with positron emission tomography.
View article: WITHDRAWN: Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models
WITHDRAWN: Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian cancer xenograft models Open
Purpose. There are no currently approved non-invasive methods for detecting tumor treatment responses within the first few days of treatment. The monoclonal antibody, DAB4, or its chimeric derivative, chDAB4 (APOMAB ® ), targets…
View article: WITHDRAWN: Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models
WITHDRAWN: Positron Emission Tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models Open
Purpose. There are no currently approved non-invasive methods for detecting tumor treatment responses within the first few days of treatment. The monoclonal antibody, DAB4, or its chimeric derivative, chDAB4 (APOMAB ® ), targets…
View article: Zirconium and copper immunoPET imaging agents for the diagnosis of cancer
Zirconium and copper immunoPET imaging agents for the diagnosis of cancer Open
View article: <i>In Vitro</i> and <i>In Vivo</i> Evaluation of <sup>89</sup>Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
<i>In Vitro</i> and <i>In Vivo</i> Evaluation of <sup>89</sup>Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy Open
Background: DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific binding to DR5. DS-8273a is currently being used in clinical Phase I tria…
View article: Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies
Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies Open
Correction for ‘A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies’ by Stacey E. Rudd et al., Chem. Commun., 2016, DOI: 10.1039/c6cc05961a.